Comparison of Aspirin and Rivaroxaban for Postoperative Venous Thromboembolism Prevention

Introduction to the Study

A recent publication in The New England Journal of Medicine examined the effectiveness of aspirin versus rivaroxaban as a preventive treatment for venous thromboembolism following knee replacement surgery. Data from the Canadian Joint Replacement Registry indicates that Canada performs over 80,000 hip and knee arthroplasties annually. Knee replacement surgery, or knee arthroplasty, is primarily conducted to relieve pain associated with osteoarthritis and is also advised for patients whose knee function is severely compromised due to injuries or other medical conditions. During the procedure, the weight-bearing surface of the knee is replaced with biocompatible materials that imitate the natural knee joint.

Postoperative Complications

Despite the popularity of knee replacement surgery, patients may experience several complications during recovery. Common postoperative issues include infections, pain, implant problems, and notably, the formation of blood clots, which can lead to deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT occurs when a clot travels through the bloodstream and lodges in a major vein, potentially impacting blood flow. Symptoms may include pain, swelling, tenderness, and discoloration in the affected area, with severe cases posing life-threatening risks. Collectively, DVT and PE are termed venous thromboembolism (VTE), affecting nearly 60% of patients undergoing complex orthopedic surgeries. To mitigate these risks, orthopedic surgeons frequently prescribe anticoagulants after surgery.

Evaluating Rivaroxaban and Aspirin

Rivaroxaban, a prescription-only anticoagulant commonly used post-surgery, is significantly more expensive than aspirin. In a study funded by the Canadian Institute of Health Research, researchers analyzed adverse bleeding events in over 3,400 patients receiving either aspirin or rivaroxaban after hip or knee replacement surgery across 15 Canadian hospitals. The study involved equal groups of patients undergoing hip and knee arthroplasties. All participants received 10 mg of rivaroxaban for five days post-surgery. Subsequently, half were switched to 80 mg of aspirin, while the others continued with rivaroxaban.

Study Findings and Implications

The study’s results, published in The New England Journal of Medicine, involved approximately 1,700 patients in each group. Venous thromboembolism occurred in 11 patients treated with aspirin and 12 patients treated with rivaroxaban, resulting in a minimal difference of 0.06%. Serious bleeding events were also comparable, with eight occurrences in the aspirin group and five in the rivaroxaban group. The 90-day follow-up indicated that aspirin could effectively replace rivaroxaban for preventing venous thromboembolism post-surgery. This finding aligns with previous studies suggesting that aspirin and heparin provide similar effectiveness in preventing postoperative thromboembolic events. Overall, these findings suggest that the more affordable and widely available aspirin may serve as a clinically proven alternative to pricier oral anticoagulants in postoperative care following knee replacement surgery.

References

(1) Anderson, D. R., Dunbar, M., Murnaghan, J., Kahn, S. R., Gross, P., Forsythe, M., Vendittoli, P. A. (2018). Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. N Engl J Med, 378(8), 699-707. doi:10.1056/NEJMoa1712746

(2) Anderson, D. R., Dunbar, M. J., & Kahn, S. R. (2013). Aspirin versus low-molecular-weight heparin after total hip arthroplasty. Ann Intern Med, 159(7), 502-503. doi:10.7326/0003-4819-159-7-201310010-00018.

https://secure.cihi.ca/estore/productSeries.htm?pc=PCC534